Dow Jones
39.112,16 -299,05 (-0,76%) Nasdaq
17.717,65 +220,84 (+1,26%) Nikkei 225
39.705,13 +531,98 (+1,36%) EUR/USD
1,0708 -0,0008 (-0,07%) Bitcoin EUR
57.508,07 +582,50 (+1,02%) CMC Crypto 200
1.278,82 -4,96 (-0,39%)
Elicio Therapeutics, Inc. (ELTX)
Dopo ore:
| Chiusura precedente | 7,14 |
| Aperto | 7,19 |
| Denaro | 0,00 x 0 |
| Domanda | 0,00 x 0 |
| Min-Max giorno | 6,79 - 7,20 |
| Intervallo di 52 settimane | 2,96 - 11,45 |
| Volume | |
| Media Volume | 47.521 |
| Capitalizzazione | 69,838M |
| Beta (mensile su 5 anni) | N/D |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -3,82 |
| Prossima data utili | 09 ago 2024 - 13 ago 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 10,00 |
GlobeNewswireElicio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC 2023) Annual Meeting
BOSTON, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that it will present updated preliminary data from the ongoing Phase 1 (AMPLIFY-201) study of its lead asset, ELI-002, targeting mutated KRAS in patients with high relapse risk pancreatic and colorectal cancers, and preclinical data on ELI-007 and EL
- GlobeNewswire
Elicio Therapeutics Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 at AACR Special Conference: Pancreatic Cancer
ELI-002 2P is an investigational therapeutic cancer vaccine targeting solid tumors driven by G12D and G12R mutations in KRASAs of the April 25, 2023 data cut-off date, among the 22 evaluable patients, preliminary data from the trial suggest that those with greater than median T cell response had not reached median Relapse-Free Survival compared to median RFS of 3.91 months for patients with less than median T cell response Updated data demonstrated 86% reduction in risk of progression or death i
- GlobeNewswire
Elicio Therapeutics Receives $2.6 Million Grant from the Gastro-Intestinal (GI) Research Foundation to Fund Research for Two Therapeutic Cancer Vaccines
Funds will advance research into ELI-007, a mutant BRAF-peptide vaccine, and ELI-008, a p53 hotspot mutation-peptide vaccine, with the aim of developing multivalent cancer vaccines targeting several mutations This $2.6 million grant is an addition to the $2.8 million that GIRF awarded Elicio in September 2022 BOSTON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel
